Table 2.
Sensitivity analysis on “high quality” studies (NOS≥8).
| Item | N of studies | N of patients/controls | MD (95% CI) | I2 | P-value |
|---|---|---|---|---|---|
| PA vs. EH | |||||
| Serum calcium | 4 | 466/532 | -0.03 (-0.09, 0.03)* | 84% | <0.01 |
| Urine calcium | 3 | 456/350 | 0.76 (0.41, 1.12) | 0% | 0.50 |
| Serum PTH | 4 | 466/532 | 2.59(1.69, 3.50) | 82% | <0.01 |
| Serum 25-OHD | 4 | 466/532 | -1.51 (-6.43, 3.41) | 60% | 0.06 |
| Before-treatment vs. After-treatment PA | |||||
| Serum calcium | 7 | 323/323 | -0.08 (-0.11, -0.05) | 70% | <0.01 |
| Urine calcium | 6 | 284/284 | 2.17 (1.70, 2.65) | 0% | 0.66 |
| Serum PTH | 8 | 354/354 | 3.19 (2.03, 4.36) | 90% | <0.01 |
| Serum 25-OHD | 7 | 305/305 | -7.00 (-14.13, 0.13)* | 76% | <0.01 |
| Unilateral vs. Bilateral PA | |||||
| Serum calcium | 5 | 338/285 | -0.03 (-0.04, -0.01)* | 35% | 0.19 |
| Urine calcium | 3 | 245/211 | 0.20 (-0.24, 0.64) | 40% | 0.19 |
| Serum PTH | 5 | 338/285 | 1.54 (1.04, 2.04) | 0% | 0.51 |
| Serum 25-OHD | 5 | 338/285 | -4.94 (-7.87, -2.00) | 0% | 0.93 |
N, number; MD, mean difference; 95% CI, 95% Confidence Intervals; * MD results changed after excluding “low quality” studies.